Advances in Brief

High Frequency of p16 (CDKN2/MTS-1/INK4A) Inactivation in Head and Neck Squamous Cell Carcinoma

Andre L. Reed, Joseph Califano, Paul Cairns, William H. Westra, Richard M. Jones, Wayne Koch, Steven Ahrendt, Yolanda Eby, Duane Sewell, Homaira Nawroz, Jiri Bartek, and David Sidransky

Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division [A. L. R., J. C., P. C., R. M. J., W. K., Y. E., D. S., H. N., D. S.], Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196; Departments of Pathology [W. H. W.] and General Surgery [S. A.], Johns Hopkins Hospital, Baltimore, Maryland 21287; and Danish Cancer Society, Division for Cancer Biology, Strandboulevarden 49, c/o. Bygn. 4, DK-2100 Copenhagen Ø, Denmark, [J. B.]

Abstract

The tumor suppressor gene p16 (CDKN2/MTS-1/INK4A) can be inactivated by multiple genetic mechanisms. We analyzed 29 invasive primary head and neck squamous cell carcinomas (HNSCC) for p16 inactivation with immunohistochemistry utilizing a monoclonal antibody (mAb), DCS-50. p16 staining of the primary lesions was correlated with genetic analysis including: (a) detailed microsatellite analysis of markers at the p16 locus to detect homozygous deletion; (b) sequence analysis of p16; and (c) Southern blot analysis to determine the methylation status of the 5' CpG island of p16. Twenty-four of 29 (83%) head and neck squamous cell carcinoma tumors displayed an absence of p16 nuclear staining using immunohistochemistry. Of these 24 tumors, we found that 16 (67%) harbored homozygous deletions, 5 (21%) were methylated, 1 displayed a rearrangement at the p16 locus, and 1 displayed a frameshift mutation in exon 1. These data suggest that: (a) inactivation of the p16 tumor suppressor gene is a frequent event in squamous cell carcinomas of the head and neck; (b) p16 is inactivated by several distinct and exclusive events including homozygous deletion, point mutation, and promoter methylation; and (c) immunohistochemical analysis for expression of the p16 gene product is an accurate and relatively simple method for evaluating p16 gene inactivation.

Introduction

HNSCCs comprise 5% of the 1,040,000 new cancers afflicting Americans annually; however, little is known about the molecular changes associated with oncogenesis (1, 2). Perturbations in cellular proliferation driven by the accumulation of genetic alterations in oncogenes and tumor suppressor genes give rise to neoplasms (3). Tumor suppressor gene inactivation is among the most common genetic mechanisms resulting in malignant transformation (4). For example, mutational inactivation of the p53 tumor suppressor gene is one of the most common genetic changes in human cancer, and it is also found in approximately 45% of primary HNSCCs (5, 6).

Evidence for inactivation of additional tumor suppressor genes in HNSCC is supported by frequent and early LOH at the 9p21 locus in these neoplasms (7). Located within this minimal region is the putative tumor suppressor gene p16 (CDKN2/MTS-1/INK4A; Refs. 8 and 9). The p16 gene encodes a cell cycle protein which inhibits cyclin-dependent kinases 4 and 6, preventing phosphorylation of Rb protein and causing inhibition of cell cycle progression from G1 to S-phase (10–12). Genetic alterations of the p16 gene lead to its inactivation, resulting in deregulation of cell proliferation and tumorigenesis. Previous reports suggest that the incidence of p16 gene mutations in HNSCC cell lines (44%) is much greater than that found in primary HNSCC tumors (10%; Refs. 13 and 14). This would suggest that the gene encoding p16 may not be the primary target of LOH at 9p21 in HNSCC, implicating the existence of (an) additional tumor suppressor genes at this locus. However, alternative mechanisms of p16 inactivation include homozygous deletion (8, 15) and methylation (16) of the 5' CpG island within the promoter region leading to p16 inactivation. For most tumor types, these alternative mechanisms of p16 inactivation are much more frequent than point mutation alone (14).

To delineate the role of p16 as a tumor suppressor in the genesis of HNSCC, we examined 29 primary HNSCC tumors for p16 gene inactivation using IHC and correlated these findings with genetic analysis of the p16 locus. We found that p16 is the most commonly inactivated tumor suppressor gene detected thus far in primary HNSCC and that immunohistochemistry is a sensitive method of detecting p16 inactivation.

Materials and Methods

Primary Tumor and Margin Samples and DNA Extraction. Twenty-nine randomly selected primary HNSCC tumors were collected from July 1996 through August 1996 following surgical resection with prior consent from Johns Hopkins Hospital patients. These specimens were fresh frozen, then microdissected on a cryostat to select for greater than 70% neoplastic cells/tumor. Blood was obtained by venipuncture from patients, and lymphocyte DNA was isolated as described for use as a normal control (7).

Histopathology. Fresh-frozen specimens were embedded in OCT (Tissue-Tek; Miles, Elkhart, IN). Tissue sections (5 mm) were cut on a cryostat, and the first two sections of each tumor were mounted on lysine-coated glass slides and stained with H&E. These slides were examined by a pathologist (W. H. W.), and microdissection was performed as needed to obtain greater than 70% neoplastic cells/tumor. Blood was obtained by venipuncture from patients, and lymphocyte DNA was isolated as described for use as a normal control (7).

Received 5/7/96; accepted 6/28/96.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Lung Spore Grant CA-58184-01 and a Collaborative Research Agreement between Oncor, Inc. (Gaithersburg, MD).

2 Oncor, Inc. provided research funding for the study described in this article. Under an agreement between Oncor and The Johns Hopkins University, Dr. Sidransky is entitled to a share of sales royalty received by the University from Oncor. Under that agreement, the University and Dr. Sidransky also have received Oncor stock which, under University policy, cannot be traded until 2 years after the first commercial sales of the products related to this research. Dr. Sidransky also serves as a member of the Scientific Advisory Board of OncorMed, Inc., an oncology subsidiary, which is commercializing some of Oncor's technology. The terms of this arrangement have been reviewed and approved by the University in accordance with its conflict of interest policies.

3 To whom requests for reprints should be addressed, at Head/Neck Surgery, Johns Hopkins University School of Medicine, 518 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21205-2196.

4 The abbreviations used are: HNSCC, head and neck squamous cell carcinoma; LOH, loss of heterozygosity; IHC, immunohistochemistry; mAb, monoclonal antibody.

Downloaded from cancerres.aacrjournals.org on April 14, 2017. © 1996 American Association for Cancer Research.
mAb in a 1:500 dilution overnight at 4°C. Immunolocalization was performed with the use of the Vectastain Elite ABC kit (Burlingame, CA), 3,3'-diaminobenzidine tetrahydrochloride (Vector, Burlingame, CA), chromagen, and nickel enhancement was used to localize p16 mAb binding in tissue sections. After 3,3'-diaminobenzidine tetrahydrochloride development, tissues were counterstained using Gill’s hematoxylin and mounted in an aqueous medium. The slides were evaluated by three observers (W. H. W., J. C., A. L. R.) using standard light microscopy. A squamous cell carcinoma of the larynx cell line (JHU-020-SCC-L) with a homozygous deletion of p16 was used as a negative control. H82, a Rb−/− small cell lung cancer cell line was used as a positive control. For nonspecific staining, normal preimmune mouse serum (Vector) was used as a background control. Only nuclear staining was regarded as positive staining. Inflammatory cells and reactive stromal cells served as positive internal controls.

Allelic Loss. Nine polymorphic microsatellite markers at the p16 locus on chromosome 9p21 were amplified using PCR analysis to detect dinucleotide repeat polymorphisms in primary HNSCC tumor DNA and corresponding blood lymphocyte DNA. Criteria for the detection of LOH and homozygous deletions have been described previously (15). Determination of homozygous deletion was based on the presence of one or more closely spaced microsatellite markers demonstrating apparent retention when flanked by markers showing clear LOH. This apparent retention is due to low level amplification of normal alleles from small amounts of nonneoplastic cells within the primary tumor without any contribution of the homozygously deleted region from the neoplastic cells (15). Primer sequences can be obtained from Research Genetics (Huntsville, AL; D9S162, IFN-α, D9S171, and D9S736) or from the Genome Database (Johns Hopkins University, Baltimore, MD; D9S1747-52).

Results

Loss of p16 Expression Using IHC Analysis. We obtained 29 primary invasive HNSCCs and analyzed them for p16 inactivation using IHC. Following DNA isolation, fresh-frozen tumor sections were stained using the p16 monoclonal antibody DCS-50 (12). In each experiment, a positive control cell line (H82) showed strong staining of the nuclei with scant cytoplasmic staining, whereas the negative control cell line (JHU-020-SCC-L) was consistently devoid of nuclear staining but exhibited slight, diffuse cytoplasmic staining. Twenty-four (83%) of the HNSCC tumors demonstrated a complete absence of p16 nuclear staining. In all cases, strong nuclear staining was observed in reactive stromal fibroblasts and lymphocytes (Fig. 1). Positive staining was not observed when the sections were reacted with nonspecific mouse serum at a 1:1000 dilution.

Genetic Analysis. Fine mapping of the 29 HNSCC tumors using closely spaced microsatellite markers at the p16 locus detected the presence of a homozygous deletion in 16 of the 24 (67%) tumors with absent staining using IHC. Conversely, homozygous deletions were not detected in any of the tumors which expressed p16 using IHC. Fig. 2 shows LOH in two primary HNSCC tumors, in which the microsatellite markers at p16 display apparent retention of heterozygosity. This apparent retention occurs from amplification of residual normal cells within the primary tumor since the homozygously deleted region within the neoplastic cells does not provide a template for amplification. This analysis has been previously compared with the presence of homozygous deletion using standard Southern blot analysis and fluorescence in situ hybridization in primary tumors (15).
HIGH FREQUENCY OF p16 INACTIVATION IN HNSCC

Fig. 2. Demonstration of homozygous deletions by microsatellite analysis. A, primary head and neck tumor showing apparent retention of heterozygosity, indicating homozygous deletion at D9S1747 flanked by LOH indicated by loss of the lower allele at D9S171 and D9S1748. B, primary head and neck tumor showing apparent retention of heterozygosity, indicating homozygous deletion at D9S1747 flanked by LOH indicated by loss of the upper allele in D9S1747, D9S1749, and at D9S171. p16 is located between D9S1747 and D9S1748, and the distance between these two markers is approximately 100 kb. N, normal tissue; T, tumor tissue.

Southern Blot Analysis of p16 Methylation Status. Exon 1 of p16 was used as a probe for Southern blot analysis on genomic DNA from 11 of 13 tumors, without a homozygous deletion of the region (by microsatellite analysis), to assess p16 inactivation due to promoter methylation. Five tumors exhibited methylation and one tumor demonstrated a rearrangement event at the p16 locus. We did not detect additional homozygous deletions with this analysis. Fig. 3 is a Southern blot showing p16 methylation in several samples and the rearrangement in tumor 18. This methylation has been previously associated with the transcriptional block of p16 in cell lines (16, 19). All five tumors with methylation (and one with rearrangement) displayed a complete absence of p16 staining using IHC. Furthermore, the methylation status of these tumors was independently confirmed in a blinded manner using a novel PCR-based methylation assay (20).

DNA Sequencing Results of Exons 1 and 2. Sequencing of exons 1 and 2 in the same tumors noted above revealed one tumor with a polymorphism in exon 2 and one tumor with a frameshift mutation in exon 1. The somatic mutation would be expected to make aberrant or truncated protein and was negative for p16 staining. All molecular analysis was performed blinded with respect to the IHC staining. Table 1 compiles the results in all 29 tumors correlated with IHC staining. Absence of IHC staining of p16 in our hands demonstrated a near perfect correlation with p16 gene inactivation by homozygous deletion, methylation, or point mutation. In one tumor with absent p16 staining (tumor 28), we could not identify a genetic alteration.

Discussion

We have demonstrated that the p16 tumor suppressor gene is frequently targeted in primary HNSCC. This is the first comprehensive analysis of the mechanisms and frequency of p16 gene inactivation in primary HNSCC. Analysis of p16 is fraught with difficulties in primary tumors for several reasons. First, multiple mechanisms of p16 inactivation warrant extensive genetic studies, including a search for homozygous deletions, methylation, and point mutations. Second, standard methods to assess homozygous deletions and methylation status require large amounts of tumor DNA of excellent quality. Even with large amounts of tumor DNA, homozygous deletions can easily escape detection due to the masking effect of nonneoplastic cells.

We have shown that IHC analysis is a straightforward method to detect p16 inactivation regardless of the precise genetic mechanisms involved. Our results demonstrate an excellent correlation between IHC and genetic analysis. Thus, IHC analysis appears to be a reliable and practical alternative to a comprehensive genetic analysis of p16 status. Others have described the use of IHC analysis in some primary tumors with a polyclonal antibody (21, 22). In one preliminary study of
non-small cell lung carcinomas, the investigators generated similar results [38/61 (63%) tumors displayed the absence of p16 staining], with a high frequency of p16 inactivation (23). Although these data support our observations, it was not combined with detailed genetic analysis. Moreover, our use of a mAb that does not cross-react with other proteins was not combined with detailed genetic analysis. More recently, we used only fresh-frozen tissue, yielding reproducible and consistent results (20-22). We considered this possibility remote because we used only fresh-frozen tissue, yielding reproducible staining results.

Allelic loss at 9p21 occurs frequently and early in HNSCC (7). It is not yet known whether p16 inactivation is the target of this early loss event in primary HNSCC. Although further investigation is required to determine the temporal occurrence of p16 loss in HNSCC, this study suggests that the inactivation of p16 may be the most common genetic change delineated in primary invasive HNSCC.

References
High Frequency of $p16$ ($CDKN2/MTS-1/INK4A$) Inactivation in Head and Neck Squamous Cell Carcinoma

Andre L. Reed, Joseph Califano, Paul Cairns, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/56/16/3630

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.